MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
119.54
-0.56
-0.47%
Opening 12:33 12/07 EST
OPEN
119.59
PREV CLOSE
120.10
HIGH
121.39
LOW
118.20
VOLUME
184.76K
TURNOVER
14.35M
52 WEEK HIGH
127.32
52 WEEK LOW
61.28
MARKET CAP
10.49B
P/E (TTM)
-14.5619
1D
5D
1M
3M
1Y
5Y
Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 5d ago
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2022 that were previously approved by the Compensation Committee...
GlobeNewswire · 6d ago
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.
Zacks · 11/29 17:07
US STOCKS-Wall St losses limited as Amazon gains on upbeat Cyber Monday
Reuters · 11/28 15:40
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
The FDA said Monday it will perform a speedy review of Sarepta Therapeutics' muscular dystrophy gene therapy, and SRPT stock jumped.
Investor's Business Daily · 11/28 14:28
BRIEF-Sarepta Therapeutics Says FDA Accepts Gene Therapy Biologics License Filing
Reuters · 11/28 12:17
Sarepta Therapeutics Announces That U.S. FDA Has Accepted For Filing And Granted Priority Review For The Biologics License Application For SRP-9001, Sarepta's Gene Therapy For The Treatment Of Ambulant Individuals With Duchenne Muscular Dystrophy
Benzinga · 11/28 12:05
Sarepta Says Its Application to Expedite Approval of Duchenne Muscular Dystrophy Treatment Secured US FDA Acceptance
Sarepta Says Its Application to Expedite Approval of Duchenne Muscular Dystrophy Treatment Secured US FDA Acceptance
MT Newswires · 11/28 07:53
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (Duchenne), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) disorders. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection. These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes more than 40 programs at various stages of discovery, pre-clinical and clinical development.

Webull offers kinds of Sarepta Therapeutics Inc stock information, including NASDAQ:SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.